Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Dihydroxypropyl Theophylline Injection from the National Medical Products Administration, indicating successful completion of the consistency evaluation for generic drug quality and efficacy [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., is responsible for the Dihydroxypropyl Theophylline Injection [1] - The approval was granted through a supplementary application, with the notification number 2025B04012 [1] - The drug has passed the consistency evaluation for quality and efficacy as a generic medication [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Dihydroxypropyl Theophylline Injection from the National Medical Products Administration, indicating successful consistency evaluation for generic drug quality and efficacy [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., has been granted a Supplementary Application Approval Notice for Dihydroxypropyl Theophylline Injection [1] - The drug is indicated for bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and symptoms of dyspnea due to cardiogenic pulmonary edema [1] - The company has invested approximately RMB 3.05 million in research and development for this drug as of the announcement date [1] Group 2: Market Insights - According to IQVIA data, the procurement amount for Dihydroxypropyl Theophylline Injection (2ml: 0.3g) in hospitals across mainland China for 2024 is RMB 9.737 million [2] - Major domestic manufacturers of this drug include Jilin Jingsheng Pharmaceutical Co., Shanxi Taiyuan Pharmaceutical Co., and Suicheng Pharmaceutical Co., Ltd. [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於二羥丙茶鹼注射液通過仿製藥一致性評價的公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 9 月 5 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称 ...

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of its Dihydroxypropyl Theophylline Injection by the National Medical Products Administration, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., received the approval notification for Dihydroxypropyl Theophylline Injection [1] - The injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and can also be used for wheezing due to cardiogenic pulmonary edema [1]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.07% on September 4, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - HeFu China (603122) with a closing price of 6.66, up 1.99% [1] - JianZhiJia (605266) at 21.56, up 1.84% [1] - YiXinTang (002727) at 14.98, up 1.70% [1] - Saily Medical (603716) was the biggest loser, closing at 29.00, down 2.26% [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - YiXinTang (002727) had a trading volume of 144,800 hands and a transaction value of 216 million [1] - Saily Medical (603716) recorded a trading volume of 256,800 hands with a transaction value of 759 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 169 million from institutional investors, while retail investors had a net inflow of 210 million [2] - Key stocks with significant capital flow included: - BaiYang Pharmaceutical (301015) with a net inflow of 15.09 million from institutional investors [3] - LaoBaiXing (603883) with a net inflow of 13.41 million from institutional investors [3]

Core Viewpoint - Goldman Sachs reported that Shanghai Pharmaceuticals (02607) had a second-quarter sales of 70.8 billion RMB, a year-on-year increase of 2.3%, which was below expectations, indicating continued weakness across various market segments [1] Financial Performance - The second-quarter recurring net profit was consistent with well-controlled expenditures, but was partially offset by a decline in gross margin [1] - The decline in gross margin was primarily attributed to the ongoing decrease in manufacturing profit margins [1] Earnings Forecast - Goldman Sachs adjusted the company's earnings forecasts for this year, next year, and 2027 to an increase of 33.5%, a decrease of 0.3%, and a decrease of 6.4%, respectively [1] - The target price was lowered from 10.29 HKD to 10.08 HKD, maintaining a "Sell" rating [1]

Core Viewpoint - Goldman Sachs reports that Shanghai Pharmaceuticals (601607)(02607) experienced a second-quarter sales revenue of 70.8 billion RMB, a year-on-year increase of 2.3%, which is below expectations, indicating continued weakness across various market segments [1] Financial Performance - The second-quarter recurring net profit was consistent with well-controlled expenditures, but was partially offset by a decline in gross margin [1] - The decline in gross margin is primarily attributed to the ongoing decrease in manufacturing profit margins [1] Earnings Forecast - The company’s earnings forecasts for this year, next year, and 2027 have been adjusted to an increase of 33.5%, a decrease of 0.3%, and a decrease of 6.4%, respectively [1] - The target price has been lowered from 10.29 HKD to 10.08 HKD, while maintaining a "Sell" rating [1]

证券代码：601607 证券简称：上海医药 编号：临 2025-081 上海医药集团股份有限公司 关于二羟丙茶碱注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海信谊金朱 药业有限公司（以下简称"信谊金朱"）的二羟丙茶碱注射液（以下简称"该药 品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充 申请批准通知书》（通知书编号：2025B04012），该药品通过仿制药质量和疗 效一致性评价。 一、该药品基本情况 药物名称：二羟丙茶碱注射液 剂型：注射剂 规格：2ml:0.3g 注册分类：化学药品 药品批准文号：国药准字 H20258173 申请人：上海信谊金朱药业有限公司 审批结论：批准本品增加 2ml:0.3g 规格的补充申请，核发药品批准文号，本 品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 二羟丙茶碱注射液适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓 解喘息症状。也可用于因心源性肺水肿而致的喘 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for its Dihydrocodeine Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Dihydrocodeine Injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The drug can also be used for alleviating symptoms caused by pulmonary edema due to heart disease [1]